• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Societal CDMO

    Lannett CDMO

    TaiMed Biologics

    CMC Pharmaceuticals

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Societal CDMO

    Lannett CDMO

    TaiMed Biologics

    CMC Pharmaceuticals

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    05 Merck

    ...

    07.20.18
    Headquarters: Whitehouse Station, NJ
    twitter.com/Merck
    www.merck.com

    Headcount:  69,000
    Year Established:  1889
    Revenues: $40,122  (+1%)
    Pharma Revenues:  $35,390  (+1%)
    Net Income:  $2,592  (-34%)
    R&D:  $9,982  (-1%)

    TOP SELLING DRUGS  
    Drug Indication 2017 Sales (+/-%)
    Keytruda cancer $3,809 171%
    Januvia diabetes, obesity $3,737 -4%
    Gardasil HPV vaccine $2,308 6%
    Janumet diabetes, obesity $2,158 -2%
    Proquad vaccines $1,676 2%
    Zepatier hepatitis C $1,660 200%
    Zetia cholesterol $1,344 -48%
    Isentress HIV/AIDS $1,204 -13%
    Remicade rheumatoid arthritis $837 -34%
    Simponi rheumatoid arthritis $819 7%

    Merck’s worldwide pharma sales were $35.4 billion in 2017. It marks just a 1% increase compared with 2016 driven primarily by the launches of Keytruda, Zepatier and Bridion. In addition, revenue in 2017 benefited from the sale of vaccines in the markets that were previously part of the now-terminated vaccines joint venture with Sanofi Pasteur. Growth in these areas was largely offset by the effects of generic and biosimilar competition that resulted in sales declines for products including Zetia, Vytorin, Cubicin and Remicade.

    Strengthening its position in oncology, during the year Merck teamed up with Astrazeneca in a $8.5 billion global oncology pact to co-develop and co-commercialize AstraZeneca’s Lynparza for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.

    Lynparza’s pipeline has grown significantly in the last few years, with 14 indications currently being developed across several tumor types, including breast, prostate and pancreatic cancers. The strategic collaboration is expected to further increase the number of treatment options available to patients.

    The companies will develop and commercialize Lynparza jointly, both as monotherapy and in combination trials with other potential medicines. Independently, the companies will develop and commercialize Lynparza in combinations with their respective PD-L1 and PD-1 medicines, Imfinzi and Keytruda.

    The companies will also jointly develop and commercialize AstraZeneca’s selumetinib, an oral, potent, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications including thyroid cancer.

    Merck is paying AstraZeneca $1.6 billion upfront, $750 million for certain license options and up to an additional $6.15 billion in milestones.

    More Keytruda collaborations
    In addition to the oncology alliance with Astrazeneca, Merck has a number of ongoing research collaborations related to its top selling cancer drug Keytruda. A clinical collaboration with Aduro Biotech is investigating the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Keytruda for the treatment of gastric cancer.

    Also, Eli Lilly and Co. expanded its immuno-oncology collaboration with Merck to add a new study of Lilly’s Lartruvo with Keytruda in patients with previously treated advanced or metastatic soft tissue sarcoma. Lilly will conduct the Phase I study, which began mid-2017.

    Atara Biotherapeutics entered into a clinical trial collaboration agreement with Merck to evaluate Atara’s allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL), or ATA129, in combination with Keytruda, in patients with platinum resistant or recurrent EBV-associated NPC. The Phase 1/2 trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination.

    PDS Biotechnology, a clinical stage biopharma company developing immunotherapies, teamed up with a subsidiary of Merck to evaluate the combination of PDS’ lead Versamune-based immunotherapy, PDS0101, with Keytruda in a Phase II trial. The trial will evaluate the safety and efficacy of the combination in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy. Further details were not disclosed.

    Sellas Life Sciences Group, a development-stage biopharma company focused on cancer immunotherapies, entered a clinical trial collaboration and supply agreement with Merck for the conduct of a combination clinical trial targeting multiple cancers. Sellas’ Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with Keytruda in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

    Lastly, Aeglea BioTherapeutics, a biotechnology company developing enzyme-based therapeutics to treat rare genetic diseases and cancer, entered into a clinical collaboration agreement with Merck to evaluate the combination of Aeglea’s AEB1102 with Keytruda for the treatment of patients with small cell lung cancer.

    While 2017 wasn’t a big year on the M&A front for Merck, it did bolster its cancer pipeline with the purchase of Rigontec, a biotechnology company developing cancer immunotherapies, for €115 million upfront and as much as €349 million in milestone payments. Rigontec’s lead candidate, RGT100, is currently in Phase I development for the treatment of various tumors.

    Approvals and pipeline progress
    As Merck continues to expand its focus in oncology by further advancing the development program for Keytruda specifically, it received positive news from various studies and regulatory authorities in 2017.

    It announced the pivotal Phase III Keynote-189 trial investigating Keytruda in combination with pemetrexed (Alimta) and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), met its dual primary endpoints of overall survival and progression-free survival.

    Merck and The European Organization for Research and Treatment of Cancer (EORTC) revealed the Phase III EORTC1325/Keynote-054 trial investigating Keytruda as monotherapy for surgically resected high-risk melanoma met the primary endpoint of recurrence-free survival and, based on an interim analysis and following review by the Independent Data Monitoring Committee, resulted in significantly longer recurrence-free survival than placebo.

    The U.S. FDA accepted for review the supplemental Biologics License Application (sBLA) for Keytruda for the treatment of adult and pediatric patients with refractory primary mediastinal B-cell lymphoma, or who have relapsed after two or more prior lines of therapy. The FDA granted Priority Review status with a PDUFA date of April 3, 2018, and previously granted Breakthrough Therapy Designation to Keytruda in January 2017 for this indication.

    The FDA also granted Breakthrough Therapy Designation for Keytruda in combination with Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima for the potential treatment of patients with advanced and/or metastatic renal cell carcinoma, which is being jointly developed as part of a collaboration between Merck and Esai. This marks the 12th Breakthrough Therapy Designation granted to Keytruda.

    In terms of approvals, the FDA gave the ok to Lynparza for use in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy either in the neoadjuvant, adjuvant or metastatic settings. Lynparza is the first PARP inhibitor approved for breast cancer. A supplemental New Drug Application (NDA) was submitted to Japan’s Pharmaceuticals and Medical Devices Agency for the same use.

    The Japanese Ministry of Health, Labor and Welfare approved Lynparza for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy. Lynparza is also the first PARP inhibitor approved in Japan.

    Together with Pfizer, Merck announced during the year that the FDA approved Steglatro tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, the fixed-dose combination Steglujan and the fixed-dose combination Segluromet to help improve glycemic control in adults with type 2 diabetes. Additionally, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for these medicines.

    Additionally, the FDA and European Commission approved Prevymis, once-daily tablets for oral use and injection for intravenous infusion, indicated for prevention of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.

    Lastly, the FDA approved Isentress, the company’s integrase inhibitor, for use in combination with other antiretroviral agents for the treatment of HIV-1 in newborn patients from birth to four weeks of age weighing at least 2 kg. 
    Related Searches
    • vaccines
    • biotech
    • merck
    • generic
    Suggested For You
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co. Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.
    Trust, but Verify Trust, but Verify
    AltheaDx Expands Commercial Leadership Team AltheaDx Expands Commercial Leadership Team
    ImmunoGenesis Opens Research Lab, Adds Key Roles ImmunoGenesis Opens Research Lab, Adds Key Roles
    Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer
    Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD
    Drug Product Safety and Security Drug Product Safety and Security
    Batavia Manufactures IAVI’s Lassa Fever Vax Candidate Batavia Manufactures IAVI’s Lassa Fever Vax Candidate
    BioMed X Expands Collaboration with Merck BioMed X Expands Collaboration with Merck
    CureVac Appoints Dr. Malte Greune as COO CureVac Appoints Dr. Malte Greune as COO
    BioMedX Extends Collaboration with Merck BioMedX Extends Collaboration with Merck
    Too Much of a Good Thing? Too Much of a Good Thing?
    Executive Moves: Novavax Executive Moves: Novavax
    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Related Breaking News

    • Breaking News | Promotions & Moves
      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Schetter has a proven track record across the entire biopharmaceutical value chain.
      09.20.21

    • Breaking News | Clinical Trials | Collaborations & Alliances
      Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.

      Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.

      Will evaluate HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck cancers.
      09.15.21

    • Trust, but Verify

      Trust, but Verify

      Or, R.I.P, CoA.
      Emil W. Ciurczak, DoraMaxx Consulting 09.09.21


    • Breaking News
      AltheaDx Expands Commercial Leadership Team

      AltheaDx Expands Commercial Leadership Team

      Appoints Jonathan Yount as SVP, Sales and Croom Lawrence as SVP, Marketing.
      08.18.21

    • Promotions & Moves
      ImmunoGenesis Opens Research Lab, Adds Key Roles

      ImmunoGenesis Opens Research Lab, Adds Key Roles

      To support the expansion of the company's recently licensed key development assets, clinical and business development activities.
      07.28.21

    Loading, Please Wait..
    Trending
    • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
    • Samsung Biologics Accelerates Timeline Of New Fifth Plant
    • Biopharma Layoffs In 1Q23
    • Veeva Business Consulting Expands With New R&D Services
    • CRO Industry Trends & Challenges
    Breaking News
    • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    • RK Pharma to Receive $200M Investment from PAG
    • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    • TMC Expands Executive Team
    • Peli BioThermal Opens Cold Chain Network Station in Southern California
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
    Nektium Expands International Distribution Network for Botanical Extracts
    Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
    Coatings World

    Latest Breaking News From Coatings World

    PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
    Powder Technology, Inc. Announces New Electrical Coating
    Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
    ISO 13485:2016 Certification Granted to Boston BioProducts
    Paul Colvin Joins Ora Inc. as Chief Operating Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    RK Pharma to Receive $200M Investment from PAG
    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
    GetHarley Raises $52 Million in Latest Funding Round
    Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
    Happi

    Latest Breaking News From Happi

    Carrière Frères Introduces Candle Refills as New Sustainability Initiative
    Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
    The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Center of Excellence in France Receives Facelift
    Epson announces MakeTheSwitch Campaign
    Pigments Market to Reach $26,598 Million by 2022: AMR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy reports successful Low Migration Workshop
    Ryback and Ryback Consulting launches Machinery division
    TLMI launches 2023 award programs
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    The Honest Company to Exit Europe, Asia
    TechnoPlants to Exhibit at ITMA
    Andritz Buys 100% Stake in Dan-Web
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthobiologics Market to Top $10.3 Billion by 2030
    Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
    Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
    Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
    Flexible and Printed Electronics Represented at productronica 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login